Yasmina Kattou, edited by Ophélie Artaud 1:38 p.m., December 29, 2022
The Moderna laboratory is working on a messenger RNA vaccine against melanoma and has announced that the results of the first phases of its tests are encouraging.
A treatment synonymous with hope, which would be reserved for people who already have cancer at an advanced stage, and which could make it possible to fight against the risk of recurrence.
Will we soon have a vaccine against skin cancer?
This is the objective of the Moderna laboratory, which is working to market a messenger RNA vaccine against melanoma.
The results of the first test phases are encouraging.
But how would this vaccine work?
Reduce the risk of recurrence
It is a treatment, not a vaccine to prevent skin cancer.
In fact, the serum is only for people who already have advanced stage cancer.
The vaccine from Merck and Moderna laboratories would be administered to patients after the operation to remove a melanoma.
The first tests show that in parallel with taking an anti-cancer drug, several injections can reduce the risk of tumor recurrence by 44%.
>> Find Europe Midi in replay and podcast here
So far, the vaccine has been tested on 150 people.
The laboratories plan to launch phase 3 to assess the effectiveness of the treatment on a larger scale.
This last phase of testing can last up to 3 years.
If the clinical trials are conclusive, this vaccine would be a hope, because around 325,000 new cases of melanoma would have been diagnosed in 2020 worldwide.
It could hit the market by 2030.